Year All202420232022202120202019 Mar 18, 2024 Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects Mar 12, 2024 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results Mar 05, 2024 Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 Feb 26, 2024 Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 Feb 20, 2024 Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 Feb 13, 2024 Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
Mar 18, 2024 Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Mar 12, 2024 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Feb 26, 2024 Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
Feb 20, 2024 Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
